title: Downstaging Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin.
abstract: OBJECTIVE
  To investigate the effectiveness of recombinant human erythropoietin (r-HuEPO) on disease-related anemia in patients with B-chronic lymphocytic leukemia (B-CLL) and to explore whether improvement of anemia could delay the initiation of cytotoxic therapy.
  
  
  METHODS
  Twenty five B-CLL patients (12 males and 13 females; median age 70 years) with disease-related anemia were treated with r-HuEPO. Patients were either on no treatment or on a standard regimen, and had at least Rai stage III disease, with a hematocrit (Hct) <32%. Eleven were newly diagnosed, whereas 14 developed anemia during follow-up. Treatment induction lasted for a maximum of 3 months, during which patients were receiving 150 IU/kg of r-HuEPO s.c. t.i.w. with an escalation to 300 IU/kg t.i.w. if response was slow after one month. Responding patients were placed on maintenance r-HuEPO with 150 IU/kg s.c. once weekly, continuously. Complete response (CR) was defined as an increase of Hct to 38% or more and partial response (PR) as an increase of >6% from pretreatment level.
  
  
  RESULTS
  CR was observed in 18/25 (72%) and PR in 2/25 (8%) of the patients. Six patients were downstaged to stage Rai 0, 9 to Rai I and 4 to Rai II. Response was sustained with maintenance therapy. At a median follow-up of 32 months only 4 of the responders required antileukemic treatment. The median survival of responders has not been reached, and 3-year survival is 84%.
  
  
  CONCLUSIONS
  r-HuEPO was efficient in downstaging Rai stage III B-CLL patients, and delayed the initiation of antileukemic therapy. Whether this effect can be translated into better survival rates remains to be clarified in randomized trials.
authors: National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, 16 Sevastoupoleos St., P.O. Box 14044, Athens 11510, Greece. pangalis@otenet.gr
authors: Gerassimos A
authors: GA
authors: Pangalis
authors: Marina P
authors: MP
authors: Siakantaris
authors: Maria K
authors: MK
authors: Angelopoulou
authors: Theodoros P
authors: TP
authors: Vassilakopoulos
authors: Maria N
authors: MN
authors: Dimopoulou
authors: Marie-Christine
authors: MC
authors: Kyrtsonis
authors: Konstantinos
authors: K
authors: Konstantopoulos
authors: Panayiotis
authors: P
authors: Tsaftaridis
authors: George A
authors: GA
authors: Vaiopoulos
authors: Flora N
authors: FN
authors: Kontopidou
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011994:Recombinant Proteins; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin